
Virbac SA
PAR:VIRP

Virbac SA
Total Other Income
Virbac SA
Total Other Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Other Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Virbac SA
PAR:VIRP
|
Total Other Income
€420k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
90%
|
CAGR 10-Years
17%
|
|
![]() |
Sanofi SA
PAR:SAN
|
Total Other Income
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Ipsen SA
PAR:IPN
|
Total Other Income
-€40.5m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-13%
|
|
![]() |
Vetoquinol SA
PAR:VETO
|
Total Other Income
-€249k
|
CAGR 3-Years
-161%
|
CAGR 5-Years
2%
|
CAGR 10-Years
17%
|
|
![]() |
Boiron SA
PAR:BOI
|
Total Other Income
-€2.5m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
![]() |
Medincell SA
PAR:MEDCL
|
Total Other Income
€3k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Virbac SA
Glance View
Founded in 1968 in the picturesque city of Carros near Nice, France, Virbac SA has grown to become a formidable player in the animal health industry. With its roots firmly planted in the niche of veterinary medicine, the company was established by Pierre-Richard Dick, a veterinarian himself, who sought to fill a gap in high-quality veterinary products. Today, Virbac stands as one of the largest independent veterinary pharmaceutical companies, with an extensive global presence spanning more than 100 countries. The company’s portfolio is diverse, encompassing products for both livestock and pets, including vaccines, antibiotics, and specialty diets designed to enhance animal health and welfare. By focusing on R&D and maintaining robust relationships with veterinary professionals, Virbac continually develops solutions that address the evolving needs of animal care. Virbac’s business model revolves around an intricate balance of innovation and strategic market expansion. The company's revenue streams derive from its comprehensive range of products aimed at disease prevention and treatment, which serve various species such as cattle, swine, poultry, horses, cats, and dogs. By investing significantly in research and development, Virbac not only stays ahead in terms of product efficacy and safety but also navigates the regulatory landscapes across its operating regions. This drive to innovate is coupled with a meticulous marketing strategy that involves educating veterinary professionals and end-users, ensuring the optimal use of their products. As a result, Virbac successfully generates income through the direct sale of its products to veterinary clinics, distributors, and directly to pet owners, continually reinforcing its role as a trusted partner in animal health care globally.

See Also
What is Virbac SA's Total Other Income?
Total Other Income
420k
EUR
Based on the financial report for Dec 31, 2024, Virbac SA's Total Other Income amounts to 420k EUR.
What is Virbac SA's Total Other Income growth rate?
Total Other Income CAGR 10Y
17%
Over the last year, the Total Other Income growth was 1%.